TITLE

Barriers to Initiation of Antiretrovirals during Antituberculosis Therapy in Africa

AUTHOR(S)
Pepper, Dominique J.; Marais, Suzaan; Wilkinson, Robert J.; Bhaijee, Feriyl; De Azevedo, Virginia; Meintjes, Graeme
PUB. DATE
May 2011
SOURCE
PLoS ONE;2011, Vol. 6 Issue 5, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: In the developing world, the principal cause of death among HIV-infected patients is tuberculosis (TB). The initiation of antiretroviral therapy (ART) during TB therapy significantly improves survival, however it is not known which barriers prevent eligible TB patients from initiating life-saving ART. Method: Setting. A South African township clinic with integrated tuberculosis and HIV services. Design. Logistic regression analyses of a prospective cohort of HIV-1 infected adults ($18 years) who commenced TB therapy, were eligible for ART, and were followed for 6 months. Findings: Of 100 HIV-1 infected adults eligible for ART during TB therapy, 90 TB patients presented to an ART clinic for assessment, 66 TB patients initiated ART, and 15 TB patients died. 34% of eligible TB patients (95%CI: 25-43%) did not initiate ART. Male gender and younger age (,36 years) were associated with failure to initiate ART (adjusted odds ratios of 3.7 [95%CI: 1.25-10.95] and 3.3 [95%CI: 1.12-9.69], respectively). Death during TB therapy was associated with a CD4+ count ,100 cells/mL. Conclusion: In a clinic with integrated services for tuberculosis and HIV, one-third of eligible TB patients - particularly young men - did not initiate ART. Strategies are needed to promote ART initiation during TB therapy, especially among young men.
ACCESSION #
73816393

 

Related Articles

  • Delayed Progression to Death and to AIDS in a Hong Kong Cohort of Patients with Advanced HIV Type 1 Disease During the Era of Highly Active Antiretroviral Therapy. Ka Hing Wong; Kenny Chi Wai Chan; Shui Shan Lee // Clinical Infectious Diseases;9/15/2004, Vol. 39 Issue 6, p853 

    Background. The magnitude of the impact of highly active antiretroviral therapy (HAART) since its introduction in non-Western countries is not entirely clear. We studied disease progression among adult patients with advanced human immunodeficiency virus type 1 (HIV-1) infection in the pre-HAART...

  • Plasma HIV Load and Proviral DNA Decreases After Two Standard Antiretroviral Regimens in HIV-Positive Patients Naive to Antiretrovirals. Torti, Carlo; Quiros-Roldan, Maria Eugenia; Cologni, Giuliana; Nichelatti, Michele; Ceresoli, Francesca; Pinti, Marcello; Nasi, Milena; Cossarizza, Andrea; Lapadula, Giuseppe; Costarelli, Silvia; Manca, Nino; Gargiulo, Franco; Magoni, Michele; Carosi, Giampiero // Current HIV Research;Jan2008, Vol. 6 Issue 1, p43 

    (i) To compare early decrease of HIV plasma viral load (pVL) after two standard combinations of highly active antiretroviral therapy (HAART). (ii) To evaluate variations of proviral HIV-DNA load on conditions of sustained pVL undetectability. Two different sub-studies of a multicentre...

  • Antiretroviral Drugs in Pediatric HIV-Infected Patients. Phelps, B. Ryan; Rakhmanina, Natella // Pediatric Drugs;2011, Vol. 13 Issue 3, p175 

    Antiretroviral (ARY) therapy has been shown to achieve high therapeutic efficacy in treating pediatric HLV disease. The delivery of affordable, child friendly, and easy to store and administer ARV drugs is key to the successful management of HIV in children. In recent years, significant progress...

  • CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1–infected individuals. Ahuja, Sunil K.; Kulkarni, Hemant; Catano, Gabriel; Agan, Brian K.; Camargo, Jose F.; Weijing He; O'Connell, Robert J.; Marconi, Vincent C.; Delmar, Judith; Eron, Joseph; Clark, Robert A.; Frost, Simon; Martin, Jeffrey; Ahuja, Seema S.; Deeks, Steven G.; Little, Susan; Richman, Douglas; Hecht, Frederick M.; Dolan, Matthew J. // Nature Medicine;Apr2008, Vol. 14 Issue 4, p413 

    The basis for the extensive variability seen in the reconstitution of CD4+ T cell counts in HIV-infected individuals receiving highly active antiretroviral therapy (HAART) is not fully known. Here, we show that variations in CCL3L1 gene dose and CCR5 genotype, but not major histocompatibility...

  • Immune reconstitution syndrome leading to fatal invasive cerebral aspergillosis: case report.  // Reactions Weekly;7/16/2005, Issue 1060, p6 

    The article presents a case of an HIV-infected man with fatal invasive cerebral aspergillosis associated with immune reconstitution syndrome after starting antiretroviral therapy. The man received other medical treatment after weeks of antiretroviral therapy. Medical history and condition of the...

  • Providing antiretroviral treatment in Thailand.  // Report on the Global HIV/AIDS Epidemic: UNAIDS - 2004;1/1/2004, p106 

    The article offers information on the antiretroviral treatment program in Thailand. According to the author, lower drug prices have contributed to a fivefold increase in the number of human immunodeficiency virus (HIV)-positive patients receiving antiretroviral treatment in the country. It was...

  • Risk factors for default from tuberculosis treatment in HIV-infected individuals in the state of Pernambuco, Brazil: a prospective cohort study.  // BMC Infectious Diseases;2011, Vol. 11 Issue 1, p351 

    The article offers information on a study conducted on the risk factors for default from tuberculosis treatment in HIV-infected patients, in Pernambuco, Brazil. It states that Brazil has guaranteed access to antiretroviral treatment (ART) to all HIV patients, and they were classified in terms of...

  • Risk Factors for Nevirapine-Associated Rash Among HIV-Infected Patients with Low CD4 Cell Counts in Resource-Limited Settings. Kiertiburanakul, Sasisopin; Sungkanuparph, Somnuek; Charoenyingwattana, Angkana; Mahasirimongkol, Surakameth; Sura, Thanyachai; Chantratita, Wasun // Current HIV Research;Jan2008, Vol. 6 Issue 1, p65 

    Nevirapine (NVP) is commonly used as a component of first-line antiretroviral therapy in resource-limited countries. We aimed to determine the risk factors for NVP-associated rash among HIV-infected patients who were initiated NVP at low CD4 cell counts in a resource-limited setting. A...

  • A Randomized Trial of Directly Administered Antiretroviral Therapy and Adherence Case Management Intervention. Wohl, Amy Rock; Garland, Wendy H.; Valencia, Rosa; Squires, Kathleen; Witt, Mallory D.; Kovacs, Andrea; Larsen, Robert; Hader, Shannon; Anthony, Monique-Nicole; Weidle, Paul J. // Clinical Infectious Diseases;6/1/2006, Vol. 42 Issue 11, p1619 

    Background. A randomized, controlled trial was conducted to evaluate the impact of a directly administered antiretroviral therapy program (DAART) and intensive adherence case management (IACM) intervention on virologic and immunologic response to highly active antiretroviral therapy (HAART)...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics